PDEX PRO DEX (PDEX) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0000788920
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
41
13F, latest reported quarter
What the filings say about PDEX
Insiders, 180 days
-$2.0M net sold
2 sellers · 58% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.5M
2 notices
PRO DEX insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, PRO DEX INC insiders sold a net $2.0M of stock across 58 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Sep 9, 2026.
- The trade is 0.4% of the 79,703 shares held after it.
- 1 other insider sold within 30 days.
- 41 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Van Kirk Richard Lee Jr sold about $17.1K of PDEX under a 10b5-1 plan on Sep 11, 2026; 1 other insider sold within 30 days and 41 funds added in the latest 13F quarter.Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Sep 9, 2026.
- The trade is 0.6% of the 79,228 shares held after it.
- 1 other insider sold within 30 days.
- 41 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Van Kirk Richard Lee Jr sold about $28.3K of PDEX under a 10b5-1 plan on Sep 11, 2026; 1 other insider sold within 30 days and 41 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Nov 7, 2024.
- The trade is 6.6% of the 22,670 shares held after it.
- 1 other insider sold within 30 days.
- 41 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Charlton Alisha sold about $91.6K of PDEX on Sep 9, 2026; 1 other insider sold within 30 days and 41 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Nov 7, 2024.
- The trade is 3.7% of the 21,870 shares held after it.
- 1 other insider sold within 30 days.
- 41 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Charlton Alisha sold about $49.4K of PDEX on Sep 9, 2026; 1 other insider sold within 30 days and 41 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on May 22, 2026.
- The trade is 2.2% of the 97,068 shares held after it.
- 1 other insider sold within 30 days.
- 41 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Van Kirk Richard Lee Jr sold about $127.3K of PDEX under a 10b5-1 plan on Sep 9, 2026; 1 other insider sold within 30 days and 41 funds added in the latest 13F quarter.58 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$2.0M over 180 days
-$1.4M over 90 days
below 67% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
41 funds bought in last quarter
below 63% of Medical Devices
Revenue
+16.5% year over year
more than 65% of Medical Devices
Margin
17.6% net margin
more than 90% of Medical Devices
Buybacks
$3.4M repurchased, FY to 2026-06-30
below 80% of Medical Devices
Short interest
13.3% of the float short (float per yahoo 2026-10-26) · 2.9 days to cover · settled 2026-09-30
more than 71% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PDEX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+136.0%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PDEX: institutional holders (13F)
13F holdings, latest reported quarter
153,178 sh
$9.0M
82,283 sh
$4.8M
57,061 sh
$3.3M
$3.1M
49,636 sh
$2.9M
Congress trades in PDEX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PDEX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Van Kirk Richard Lee Jr
Filed 2026-09-09
$1.3M
Alisha Charlton
Filed 2026-09-08
$168.8K
PDEX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco NASDAQ Future Gen 200 ETF
$112.8K position · as of 2026-05-31
0.6%
Hartford Multifactor Small Cap ETF
$219.3K position · as of 2026-07-31
0.4%
Royce Quant Small-Cap Quality Value ETF
$44.8K position · as of 2026-06-30
0.2%
First Trust Dow Jones Select MicroCap Index Fund
$347.4K position · as of 2026-06-30
0.1%
Goldman Sachs Small Cap Growth Insights Fund
$168.9K position · as of 2026-07-31
0.1%
iShares Micro-Cap ETF
$408.8K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Rick
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$727.6K
$1.1M
$353.7K
+207%
n/a
2024
$653.0K
$1.9M
$357.8K
+126%
n/a
2023
$441.3K
$397.5K
$320.5K
+3%
n/a
2022
$418.6K
$632.1K
$297.6K
+19%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $2.0M sold by insiders over 180 days, 41 funds added last quarter, $1.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
PDEX financials
Revenue growth
+16.5%
XBRL, annual
Net margin
17.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$77.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PDEX
| FY Jun 2026 | $77.5M |
| FY Jun 2025 | $66.6M |
| FY Jun 2024 | $53.8M |
| FY Jun 2023 | $46.1M |
| FY Jun 2022 | $42.0M |
| Jun 2026 | $20.4M |
| Mar 2026 | $19.9M |
| Dec 2025 | $18.7M |
| Sep 2025 | $18.5M |
| Jun 2025 | $17.5M |
| Mar 2025 | $17.4M |
| Dec 2024 | $16.8M |
| Sep 2024 | $14.9M |
At each fiscal year end
Single quarter
Net margin, TTM
+17.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PDEX
| FY Jun 2026 | +17.6% |
| FY Jun 2025 | +13.5% |
| FY Jun 2024 | +4.0% |
| FY Jun 2023 | +15.3% |
| FY Jun 2022 | +10.9% |
| Jun 2026 | +14.0% |
| Mar 2026 | +19.7% |
| Dec 2025 | +11.7% |
| Sep 2025 | +25.3% |
| Jun 2025 | +6.8% |
| Mar 2025 | +18.8% |
| Dec 2024 | +12.1% |
| Sep 2024 | +16.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$6.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PDEX
| FY Jun 2026 | $6.8M |
| FY Jun 2025 | -$2.9M |
| FY Jun 2024 | n/a |
| FY Jun 2023 | $4.3M |
| FY Jun 2022 | -$2.5M |
| Jun 2026 | -$476.0K |
| Mar 2026 | $1.5M |
| Dec 2025 | $3.5M |
| Sep 2025 | $2.2M |
| Jun 2025 | -$266.0K |
| Mar 2025 | $574.0K |
| Dec 2024 | -$4.7M |
| Sep 2024 | $1.5M |
At each fiscal year end
Single quarter
Debt to equity
0.37x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity PDEX
| FY Jun 2026 | 0.37x |
| FY Jun 2025 | 0.42x |
| FY Jun 2024 | 0.39x |
| FY Jun 2023 | 0.41x |
| FY Jun 2022 | 0.53x |
| Jun 2026 | 0.37x |
| Mar 2026 | 0.34x |
| Dec 2025 | 0.37x |
| Sep 2025 | 0.37x |
| Jun 2025 | 0.42x |
| Mar 2025 | 0.34x |
| Dec 2024 | 0.38x |
| Sep 2024 | 0.39x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.41x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt PDEX
| FY Jun 2026 | 0.41x |
| FY Jun 2025 | -0.11x |
| FY Jun 2024 | 0.52x |
| FY Jun 2023 | 0.43x |
| FY Jun 2022 | -0.06x |
| Jun 2026 | 0.41x |
| Mar 2026 | 0.48x |
| Dec 2025 | 0.42x |
| Sep 2025 | -0.08x |
| Jun 2025 | -0.11x |
| Mar 2025 | -0.04x |
| Dec 2024 | 0.24x |
| Sep 2024 | 0.65x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+32.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PDEX
| FY Jun 2026 | +32.4% |
| FY Jun 2025 | +26.6% |
| FY Jun 2024 | +6.8% |
| FY Jun 2023 | +24.8% |
| FY Jun 2022 | +19.6% |
| Jun 2026 | +32.4% |
| Mar 2026 | +29.8% |
| Dec 2025 | +30.9% |
| Sep 2025 | +30.9% |
| Jun 2025 | +26.6% |
| Mar 2025 | +28.3% |
| Dec 2024 | +21.2% |
| Sep 2024 | +16.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+20.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PDEX
| FY Jun 2026 | +20.1% |
| FY Jun 2025 | +15.8% |
| FY Jun 2024 | +4.1% |
| FY Jun 2023 | +14.0% |
| FY Jun 2022 | +10.2% |
| Jun 2026 | +20.1% |
| Mar 2026 | +17.2% |
| Dec 2025 | +18.5% |
| Sep 2025 | +18.9% |
| Jun 2025 | +15.8% |
| Mar 2025 | +16.3% |
| Dec 2024 | +12.1% |
| Sep 2024 | +10.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+17.8%
operating income after a 24.2% effective tax rate, over long-term debt only, 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital PDEX
| FY Jun 2026 | +17.8% |
| FY Jun 2025 | +16.7% |
| FY Jun 2024 | +14.3% |
| FY Jun 2023 | +11.0% |
| FY Jun 2022 | n/a |
| Jun 2026 | +17.8% |
| Mar 2026 | +15.4% |
| Dec 2025 | +17.0% |
| Sep 2025 | +16.1% |
| Jun 2025 | +16.7% |
| Mar 2025 | +20.4% |
| Dec 2024 | +18.4% |
| Sep 2024 | +15.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+24.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PDEX
| FY Jun 2026 | +24.0% |
| FY Jun 2025 | +24.8% |
| FY Jun 2024 | +17.6% |
| FY Jun 2023 | +14.4% |
| FY Jun 2022 | +14.3% |
| Jun 2026 | +24.0% |
| Mar 2026 | +20.3% |
| Dec 2025 | +24.3% |
| Sep 2025 | +23.0% |
| Jun 2025 | +24.8% |
| Mar 2025 | +27.2% |
| Dec 2024 | +24.3% |
| Sep 2024 | +19.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
15.14x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing PDEX
| FY Jun 2026 | 14.25x |
| FY Jun 2025 | 16.16x |
| FY Jun 2024 | 32.20x |
| FY Jun 2023 | 9.74x |
| FY Jun 2022 | 13.07x |
| Jun 2026 | 14.25x |
| Mar 2026 | 13.57x |
| Dec 2025 | 11.32x |
| Sep 2025 | 10.10x |
| Jun 2025 | 16.16x |
| Mar 2025 | 17.77x |
| Dec 2024 | 23.38x |
| Sep 2024 | 19.51x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$208.6M
market value at close 2026-10-23 on 2026-09-02 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value PDEX
| FY Jun 2026 | $196.3M |
| FY Jun 2025 | $157.3M |
| FY Jun 2024 | $76.5M |
| FY Jun 2023 | $77.6M |
| FY Jun 2022 | $70.5M |
| Jun 2026 | $196.3M |
| Mar 2026 | $166.3M |
| Dec 2025 | $135.7M |
| Sep 2025 | $125.8M |
| Jun 2025 | $157.3M |
| Mar 2025 | $173.6M |
| Dec 2024 | $164.3M |
| Sep 2024 | $109.1M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.4%
TTM free cash flow over market value at close 2026-10-23
FCF yield PDEX
| FY Jun 2026 | +3.6% |
| FY Jun 2025 | -2.1% |
| FY Jun 2024 | n/a |
| FY Jun 2023 | +6.3% |
| FY Jun 2022 | -4.3% |
| Jun 2026 | +3.6% |
| Mar 2026 | +4.4% |
| Dec 2025 | +4.8% |
| Sep 2025 | -2.0% |
| Jun 2025 | -2.1% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.29x
P/E over trailing EPS growth of 52%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing PDEX
| FY Jun 2026 | 0.27x |
| FY Jun 2025 | 0.05x |
| FY Jun 2024 | n/a |
| FY Jun 2023 | 0.16x |
| FY Jun 2022 | n/a |
| Jun 2026 | 0.27x |
| Mar 2026 | 0.46x |
| Dec 2025 | 0.16x |
| Sep 2025 | 0.08x |
| Jun 2025 | 0.05x |
| Mar 2025 | 0.05x |
| Dec 2024 | 0.17x |
| Sep 2024 | 4.07x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-06 | 2025-06 | 2024-06 | 2023-06 | |
|---|---|---|---|---|
| Revenue | $77.5M | $66.6M | $53.8M | $46.1M |
| Gross profit | $24.3M | $19.5M | $14.6M | $12.7M |
| Operating income | $13.0M | $10.7M | $7.2M | $5.8M |
| Net income | $13.7M | $9.0M | $2.1M | $7.1M |
| EPS (diluted) | 4.12 | 2.67 | 0.60 | 1.95 |
| Operating cash flow | $7.2M | -$1.7M | $6.2M | $5.5M |
| Cash | $8.2M | $419.0K | $2.6M | $2.9M |
| Long-term debt | $17.5M | $15.4M | $12.0M | $12.8M |
| Buybacks | $3.4M | $3.5M | $3.5M | $1.5M |
SEC XBRL, fiscal years, as known on 2026-10-27
PDEX Stock Sonar score 6/7 axes
Find similar shapesComparePDEX ranks highest on profitability (90th percentile) and growth (65th), and lowest on insider conviction (19th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PDEX filings, in plain words
Are PRO DEX insiders buying or selling PDEX?
In the 180 days to 2026-10-27, PRO DEX insiders were net sellers, a net $2.0M across purchases and sales reported on Form 4, by 2 sellers.
Are there planned insider sales of PDEX?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $1.5M of stock; the latest, by Van Kirk Richard Lee Jr, was filed 2026-09-09.
Read the full summary
In the 180 days to 2026-10-27, PRO DEX insiders were net sellers of PDEX, a net $2.0M across purchases and sales reported on Form 4 by 2 sellers. 58% of the 19 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $1.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
